Health & Fitness
Health and Fitness
Health and Fitness
Wed, November 17, 2010
Tue, November 16, 2010
Isis Pharmaceuticals, GlaxoSmithKline, Bristol-Myers Squibb, Johnson & Johnson and Genzyme
CHICAGO--([ BUSINESS WIRE ])--Zacks.com Analyst Blog features: Isis Pharmaceuticals Inc. (Nasdaq: [ ISIS ]), GlaxoSmithKline (NYSE: [ GSK ]), Bristol-Myers Squibb (NYSE: [ BMY ]), Johnson & Johnson (NYSE: [ JNJ ]) and Genzyme (Nasdaq: [ GENZ ]).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: [ http://at.zacks.com/?id=4579 ]
Here are highlights from Mondaya™s Analyst Blog:
Loss Widens at Isis Pharma
Isis Pharmaceuticals Inc. (Nasdaq: [ ISIS ]) reported a net loss of 13 cents per share in the third quarter 2010, wider than the year-ago loss of 12 cents. The higher loss was mainly due to higher operating expenses.
However, third quarter loss was narrower than the Zacks Consensus Estimate of a net loss of 20 cents. Following the adoption of a new required accounting standard, Isis is no longer including Regulus Therapeutics' financial results.
Quarter in Detail
Third quarter revenues, which include license fees, milestone-related payments and other payments, increased 6.9% to $28.6 million. Reported revenues exceeded the Zacks Consensus Estimate of $26 million. Revenues consist of the amortization of milestone and upfront payments received from partners like GlaxoSmithKline (NYSE: [ GSK ]) and Bristol-Myers Squibb (NYSE: [ BMY ]), among others.
We note that the company finished amortizing the revenue associated with the $50 million upfront payment received from Johnson & Johnsona™s(NYSE: [ JNJ ]) Ortho-McNeil-Janssen in 2007.
Third quarter revenues included a $5 million milestone payment received by Isis under its collaboration with GlaxoSmithKline. The milestone payment relates to the selection of a suitable candidate (ISIS-GSK1Rx) which can be moved into further stages of development under the collaboration agreement.
Isis reported higher expenses during the quarter mainly due to increased costs associated with the companya™s preparations for applying for regulatory approval of lead candidate, mipomersen. The higher expenses were partially offset by the non-inclusion of expenses for Regulus.
We expect operating expenses to continue increasing as the company works on the regulatory filing of mipomersen and expands its research and development activities. Isis intends to initiate two phase II programs and two phase I programs during the fourth quarter.
Isis and partner Genzyme (Nasdaq: [ GENZ ]) intend to file for US approval in the first half of 2011. The companies intend to initially file for the treatment of patients with homozygous familial hypercholesterolemia (FH). The filing may also include patients with severe heterozygous FH.
With the initial approval, mipomersen could be addressing a patient population of about 35k people across the US, Europe and Japan.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: [ http://at.zacks.com/?id=5514 ].
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: [ http://at.zacks.com/?id=5516 ]
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at [ http://at.zacks.com/?id=4580 ].
Visit [ http://www.zacks.com/performance ] for information about the performance numbers displayed in this press release.
Follow us on Twitter: [ http://twitter.com/ZacksResearch ]
Join us on Facebook: [ http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts ]
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
